Abstract: This disclosure relates generally to crystalline polymorphs of a thiazolylpyrazole derivative, pharmaceutical compositions comprising them, and methods of using the crystalline polymorphs and their compositions.

Abstract: This disclosure relates generally to improved methods of preparing pyrazolylthiazole-containing compounds and their intermediates.

Abstract: This disclosure relates generally to improved methods of preparing pyrazolylthiazole-containing compounds and their intermediates.

Abstract: This disclosure relates generally to crystalline polymorphs of a thiazolylpyrazole derivative, pharmaceutical compositions comprising them, and methods of using the crystalline polymorphs and their compositions.

Abstract: A voltage regulator system for regulating an output voltage of a genset includes a voltage regulator for reducing terminal voltage in response to a reduction in terminal frequency. A plurality of under-frequency roll-off (UFRO) states is provided in the voltage regulator, with each UFRO state being configured to implement a UFRO characteristic. An operational signal indicative of an operating condition of the genset forms the basis for selection of the UFRO characteristic.

Abstract: A voltage regulator system for regulating an output voltage of a genset includes a voltage regulator for reducing terminal voltage in response to a reduction in terminal frequency. A plurality of under-frequency roll-off (UFRO) states is provided in the voltage regulator, with each UFRO state being configured to implement a UFRO characteristic. An operational signal indicative of an operating condition of the genset forms the basis for selection of the UFRO characteristic.

Abstract: A method of manufacturing a polyurethane compound comprises mixing together a polyol, a polyisocyanate compound and a catalyst and allowing the mixture to cure to form a polyurethane, and is characterized in that the catalyst is a neutral complex of a metal selected from Ti, Zr, Hf, Al, Fe, Bi or Sn and a multidentate organic ligand having: a) a number of anionic donor sites=x; b) a number of neutral donor sites, capable of forming a co-ordinate bond with the metal, =y; c) where x+y=from 5 to 8; d) x is from 2 to 4; e) the ligand molecule is of a size and conformation to enable each of the anionic donor sites and neutral donor sites to form a bond with the same metal atom.

Abstract: The invention provides a method of carrying out a Lewis-acid catalysed organic reaction in the presence of a Lewis acid catalyst comprising a metal-organic compound having the following formula: M(HO(CR1R2)z)a(O(CR1R2)z)bY—(CR3R4)?-Y((CR1R2)zO)c((CR1R2)zOH)d.nR5OH (Formula I) in which: M is a metal atom, preferably titanium, zirconium, hafnium or iron (III) Y is selected from P and N, but Ss very preferably N; each R1, R2, R3 and R4 is independently selected from H, alkyl, aryl, substituted alkyl or substituted aryl, R5 is hydrogen, an alkyl group, a hydroxy-functionalised alkyl group, a polyoxyalkylmoiety, R6O or R7COO where R6 and R7 may each represent H, alkyl, aryl or alkyl-aryl; d and a are each O or 1, b and c are each 1 or 2, b+c=the valency of M, a+b+c+d=4, each z is independently 1, 2, 3 or 4; x represents the least number of C atoms between the Y atoms and is 2 or 3 and n is a number in the range from 0 to 4.

Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: A method of manufacturing a polyurethane compound comprises mixing together a polyol, a polyisocyanate compound and a catalyst and allowing the mixture to cure to form a polyurethane, and is characterised in that the catalyst is a neutral complex of a metal selected from Ti, Zr, Hf, Al, Fe, Bi or Sn and a multidentate organic ligand having: a) a number of anionic donor sites=x; b) a number of neutral donor sites, capable of forming a co-ordinate bond with the metal, =y; c) where x+y=from 5 to 8; d) x is from 2 to 4; e) the ligand molecule is of a size and conformation to enable each of the anionic donor sites and neutral donor sites to form a bond with the same metal atom.

Abstract: The present invention relates to ICF (Insulated Concrete Form) building technology, offering an enhancement to existing practices by presenting a structure and method that enables concrete to be placed and shaped at any angle. In addition, the present invention provides a structure and method that offers aesthetic alternatives to flat surfaces characteristic of existing concrete forming building techniques.

Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: The present invention relates to ICF (Insulated Concrete Form) building technology, offering an enhancement to existing practices by presenting a structure and method that enables concrete to be placed and shaped at any angle. In addition, the present invention provides a structure and method that offers aesthetic alternatives to flat surfaces characteristic of existing concrete forming building techniques.

Abstract: Disclosed are novel tricyclic compounds of the formula: and the pharmaceutically acceptable salts thereof. Y is C or CH. When Y is C then Z is not present and the optional bond from Y to the C-11 carbon of the tricyclic nucleus is present. When Y is CH then Z is present and Z is H or —OH. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: The present invention provides compounds of formula I wherein X and R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.

Abstract: The present invention provides compounds of formula I wherein X, Y, R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.

Abstract: A material for the storage of hydrogen is provided comprising single wall carbon nanotubes (SWNT), wherein the majority of the diameters of the single wall carbon nanotubes of the assembly range from 0.4 to 1.0 nanometers (nm), and the average length is less than or equal to 1000 nm, or the diameters of the single wall carbon nanotubes of the assembly range from 0.4 to 1.0 nanometers (nm), and the heat (??H) of hydrogen adsorption of the material is within the range from 4 kcal/mole H2 to 8 kcal/mole H2. Processes for the storage and release of hydrogen using the materials are disclosed.

Abstract: Disclosed are novel tricyclic compounds of the formula: and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.

Abstract: Disclosed is a dispenser useful for dispensing a first liquid and retrieving a second liquid comprising a first conduit having an orifice for dispensing the first liquid, and a second conduit having an orifice for retrieving a second liquid in direction countercurrent to the first liquid. Also disclosed are methods for using a dispenser of the invention comprising placing a dispenser in communication with a first compartment and a second compartment, the dispenser comprising a first conduit having an orifice for dispensing the first liquid and a second conduit having an orifice for retrieving a second liquid in direction countercurrent to the first liquid; transferring the first liquid through the first conduit into the first compartment; and transferring the second liquid situated in the second compartment into the second conduit. The invention also relates to the use of the dispenser in a fueling process.